Your browser doesn't support javascript.
loading
Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome.
Tovy, Ayala; Rosas, Carina; Gaikwad, Amos S; Medrano, Geraldo; Zhang, Linda; Reyes, Jaime M; Huang, Yung-Hsin; Arakawa, Tastuhiko; Kurtz, Kristen; Conneely, Shannon E; Guzman, Anna G; Aguilar, Rogelio; Gao, Anne; Chen, Chun-Wei; Kim, Jean J; Carter, Melissa T; Lasa-Aranzasti, Amaia; Valenzuela, Irene; Van Maldergem, Lionel; Brunetti, Lorenzo; Hicks, M John; Marcogliese, Andrea N; Goodell, Margaret A; Rau, Rachel E.
Affiliation
  • Tovy A; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
  • Rosas C; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
  • Gaikwad AS; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.
  • Medrano G; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.
  • Zhang L; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA; Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX.
  • Reyes JM; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX.
  • Huang YH; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX.
  • Arakawa T; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
  • Kurtz K; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.
  • Conneely SE; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.
  • Guzman AG; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
  • Aguilar R; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.
  • Gao A; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.
  • Chen CW; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA; Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX.
  • Kim JJ; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA; Department of Education, Innovation and Technology, Baylor College of Medicine, Houston, TX.
  • Carter MT; Department of Genetics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
  • Lasa-Aranzasti A; Department of Clinical and Molecular Genetics, Vall d'Hebron University Hospital and Medicine Genetics Group, Vall d'Hebron Research Institute, Barcelona.
  • Valenzuela I; Department of Clinical and Molecular Genetics, Vall d'Hebron University Hospital and Medicine Genetics Group, Vall d'Hebron Research Institute, Barcelona.
  • Van Maldergem L; Centre de Génétique Humaine and Integrative and Cognitive Neuroscience Research Unit EA481, University of Franche-Comté, Besancon, France.
  • Brunetti L; Department of Medicine and Surgery, University of Perugia, Perugia.
  • Hicks MJ; Department of Pathology Texas Children's Hospital and Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX.
  • Marcogliese AN; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.
  • Goodell MA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA; Graduate Progra
  • Rau RE; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX. rachel.rau@bcm.edu.
Haematologica ; 107(4): 887-898, 2022 04 01.
Article in En | MEDLINE | ID: mdl-34092059
Tatton-Brown-Rahman syndrome (TBRS) is an overgrowth disorder caused by germline heterozygous mutations in the DNA methyltransferase DNMT3A. DNMT3A is a critical regulator of hematopoietic stem cell (HSC) differentiation and somatic DNMT3A mutations are frequent in hematologic malignancies and clonal hematopoiesis. Yet, the impact of constitutive DNMT3A mutation on hematopoiesis in TBRS is undefined. In order to establish how constitutive mutation of DNMT3A impacts blood development in TBRS we gathered clinical data and analyzed blood parameters in 18 individuals with TBRS. We also determined the distribution of major peripheral blood cell lineages by flow cytometric analyses. Our analyses revealed non-anemic macrocytosis, a relative decrease in lymphocytes and increase in neutrophils in TBRS individuals compared to unaffected controls. We were able to recapitulate these hematologic phenotypes in multiple murine models of TBRS and identified rare hematological and non-hematological malignancies associated with constitutive Dnmt3a mutation. We further show that loss of DNMT3A in TBRS is associated with an altered DNA methylation landscape in hematopoietic cells affecting regions critical to stem cell function and tumorigenesis. Overall, our data identify key hematopoietic effects driven by DNMT3A mutation with clinical implications for individuals with TBRS and DNMT3A-associated clonal hematopoiesis or malignancies.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA (Cytosine-5-)-Methyltransferases / Intellectual Disability Limits: Animals / Humans Language: En Journal: Haematologica Year: 2022 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA (Cytosine-5-)-Methyltransferases / Intellectual Disability Limits: Animals / Humans Language: En Journal: Haematologica Year: 2022 Type: Article